Drug Profile
MPC 3100
Alternative Names: MPC-3100Latest Information Update: 26 Nov 2012
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Antineoplastics; Purines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
- 11 May 2012 Myrexis intends to out-license all its preclinical and clinical programmes, including MPC 3100, for further development
- 28 Mar 2012 Adverse events and pharmacodynamics data from a phase I trial in Cancer presented at the 243rd National Meeting of the American Chemical Society (243rd-ACS-2012)